Compare
ProPhase Labs, Inc. vs China Pharma Holdings, Inc. vs Ensysce Biosciences, Inc. vs Marker Therapeutics, Inc.
| Latest fiscal year | ProPhase Labs, Inc. PRPH | China Pharma Holdings, Inc. CPHI | Ensysce Biosciences, Inc. ENSC | Marker Therapeutics, Inc. MRKR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.34M | $4.14M | $5.07M | $3.55M |
| Revenue growth (YoY) | -35.8% | -8.5% | -2.8% | -46.2% |
| Gross margin | 31.9% | -3.2% | n/a | n/a |
| Operating margin | -415.4% | -78.2% | -202.1% | -363.5% |
| Net margin | -339.3% | -76.9% | -200.8% | -343.0% |
| Net income | -$14.74M | -$3.19M | -$10.18M | -$12.16M |
| EPS (Diluted) | -$1.74 | -$0.74 | -$3.98 | -$0.79 |
| Operating cash flow | -$8.34M | $148.3K | -$7.81M | -$12.01M |
| Free cash flow | -$8.34M | $88.9K | -$7.93M | n/a |
| Cash & equivalents | $90.0K | $345.1K | $4.31M | $16.07M |
| Total assets | $59.87M | $31.00M | $7.45M | $19.07M |
| Total liabilities | $56.36M | $8.26M | $4.57M | $2.27M |
| Shareholders' equity | $3.51M | $22.74M | $3.21M | $16.80M |
| Return on year-end equity | -420.3% | -14.0% | -316.6% | -72.4% |
| Shares outstanding | 8.97M | 15.52M | 4.57M | 16.70M |
Revenue, most recent five fiscal years
| Fiscal year | ProPhase Labs, Inc. | China Pharma Holdings, Inc. | Ensysce Biosciences, Inc. | Marker Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $4.34M Ended 2025-12-31 | $4.14M Ended 2025-12-31 | $5.07M Ended 2025-12-31 | $3.55M Ended 2025-12-31 |
| 1 year earlier | $6.77M Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $5.21M Ended 2024-12-31 | $6.59M Ended 2024-12-31 |
| 2 years earlier | $34.98M Ended 2023-12-31 | $7.01M Ended 2023-12-31 | $2.23M Ended 2023-12-31 | $3.31M Ended 2023-12-31 |
| 3 years earlier | $122.65M Ended 2022-12-31 | $8.10M Ended 2022-12-31 | $2.52M Ended 2022-12-31 | $3.51M Ended 2022-12-31 |
| 4 years earlier | $79.04M Ended 2021-12-31 | $9.64M Ended 2021-12-31 | $3.53M Ended 2021-12-31 | $1.24M Ended 2021-12-31 |